

What if Half of Your Patients Moved (or Remembered or Did Something Else Bad) at Incision?

NUMBERS are part of medical education—everyone learns normal values for blood pressure, laboratory values, and so on; then, during training, one acquires numbers specific for one's specialty. One category of numbers—minimum alveolar concentration (MAC)—permeates the anesthesia community. For each inhaled anesthetic, that number is branded onto one's brain as a guide to dosing. However, there is a problem with MAC: If patients were dosed with 1 MAC, by definition, 50% of patients would move on incision. Surgeons would be unhappy, patients might be harmed, and anesthesiologists' professional standing would be compromised. Realistically, one of two things happens when inhaled anesthetics are given: Either larger doses are given routinely or movement is prevented by administration of other drugs.

One could argue that MAC, an ED₅₀, is not an inherently useful number; instead, it makes more sense to report ED₉₅ (*i.e.*, a dose preventing movement in 95% of subjects). Yet, studies of every inhaled anesthetic in the modern era have focused on ED₅₀ rather than any other measure of potency. This oddity can be explained through some history. The earliest studies of MAC, performed by Eger and associates, estimated MAC semi-quantitatively and did not apply rigorous statistical evaluation (personal communication, Edmond I. Eger II, M.D., Professor, Department of Anesthesia, University of California, San Francisco, January 30, 2007). After the first several studies were reported, Eger learned of the "up-down" method in which the dose for a particular subject in a clinical trial is selected as a function of the response of the previous subject. This method was coupled with a variety of statistical techniques to estimate ED₅₀. One advantage of these approaches was that studies could be quite small—MAC was estimated in as few as 10–20 subjects; in turn, MAC studies proliferated.

These MAC studies proved to be clinically useful, guiding numerous generations of anesthesiologists. Why would that be the case if the number that they provided

could result in a high incidence of patient movement? The answer is simple. In Eger's early studies, it became apparent that doses minimally larger than ED₅₀ typically prevented movement. For example, with halothane, in which ED₅₀ was estimated to be 0.75%, none of the subjects with end-tidal concentrations larger than 0.78% moved.¹ This observation suggested that the concentration-response relation for inhaled anesthetics was steep, *i.e.*, ED₉₅ differed minimally from ED₅₀. In turn, knowledge of ED₅₀ would have been sufficient to guide clinical dosing (and trials that formally estimated ED₉₅ for inhaled anesthetics would not be needed).

Subsequently, de Jong and Eger² formally evaluated the premise that, for inhaled anesthetics, the ratio of ED₉₅ to ED₅₀ is not markedly larger than 1. A study of nine inhaled anesthetics showed that ED₉₅ was typically less than 20% larger than ED₅₀; the ratio of ED₉₅ to ED₅₀ exceeded 25% only for ethylene and xenon (neither of which is used clinically). In that the safety margin of inhaled anesthetics is reasonably large, clinicians could dose inhaled anesthetics with concentrations sufficiently above ED₅₀ to ensure lack of movement without compromising safety; in turn, knowledge of ED₅₀ was sufficient to guide dosing (*i.e.*, "give a little more than 1 MAC and things will be OK").

Over ensuing decades, statistical techniques for the conduct/evaluation of MAC studies evolved minimally. Meanwhile, researchers in anesthesia extended traditional up-down methodologies to drugs other than inhaled anesthetics, *e.g.*, local anesthetics. Unfortunately, published studies of these other drug classes have not formally evaluated steepness of the dose-response curve; in turn, relevance of ED₅₀ to clinical dosing of anesthetic drugs other than inhaled anesthetics is understood less well. Perhaps the only evolution in statistical methods for estimation of potency of anesthetic drugs was the introduction of logistic regression to estimate ED₅₀. Although I used logistic regression in one study,³ I understand now that it can yield flawed and biased estimates⁴ (logistic regression assumes that the independent variable, concentration, is selected randomly, whereas successive values are assigned systematically).

In contrast, statistical methods for estimation of dose-response have evolved significantly in other fields, driven by needs in therapeutic areas such as oncology (for which therapeutic margins are typically small and there is a need to minimize trial size). In the current issue of ANESTHESIOLOGY, Pace and Stylianou⁴ review historic and new statistical methods for the determination of potency. Their important contribution to the anesthe-

This Editorial View accompanies the following article: Pace NL, Stylianou MP: Advances in and limitations of up-and-down methodology: A précis of clinical use, study design, and dose estimation in anesthesia research. ANESTHESIOLOGY 2007; 107:144–52.

Accepted for publication March 15, 2007. The author is not supported by, nor maintains any financial interest in, any commercial activity that may be associated with the topic of this article.

David C. Wartier, M.D., Ph.D., served as Handling Editor for this article.

sia community is the description of methods to estimate ED_g, potency at the gth percentile. The review is of particular importance to investigators who perform potency studies in which the outcome is quantal (e.g., movement *vs.* no movement). In addition, others interested in clinical research can learn much from the article.

During the review process for this article, two things became evident. First, as Paul and I⁵ reported several years ago in this journal, regardless of the methodology used for dose selection and analysis, studies with small numbers of subjects may yield biased and imprecise estimates (*i.e.*, broad confidence limits), even for ED₅₀. Second, as the potency estimate deviates further from 50% (e.g., ED₉₅), problems of bias and imprecision become worse.

The anesthesia research community has benefited from studies that had relatively small sample sizes and reported ED₅₀. If ED₅₀ is useful, this practice can prob-

ably continue without harm: The long history with inhaled anesthetics suggests that this is the case. However, for other anesthetic drugs, e.g., local anesthetics, clinical utility of ED₅₀ remains to be seen. Pace and Stylianou offer guidance on how to obtain other, possibly more useful, potency estimates.

Dennis Fisher, M.D., "P Less Than" Company, San Francisco, California. fisher@plessthan.com

References

1. Saidman IJ, Eger EI II: Effect of nitrous oxide and of narcotic premedication on the alveolar concentration of halothane required for anesthesia. *ANESTHESIOLOGY* 1964; 25:302-6
2. de Jong RH, Eger EI II: MAC expanded: AD₅₀ and AD₉₅ values of common inhalation anesthetics in man. *ANESTHESIOLOGY* 1975; 42:384-9
3. Fisher DM, Zwass MS: MAC of desflurane in 60% nitrous oxide in infants and children. *ANESTHESIOLOGY* 1992; 76:354-6
4. Pace NL, Stylianou MP: Advances in and limitations of up-and-down methodology: A précis of clinical use, study design and dose estimation in anesthesia research. *ANESTHESIOLOGY* 2007; 107:144-52
5. Paul M, Fisher DM: Are estimates of MAC reliable? *ANESTHESIOLOGY* 2001; 95:1362-70

Anesthesiology 2007; 107:2-4

Copyright © 2007, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

Anesthetic Neurotoxicity in Newborns

Should We Change Clinical Practice?

PUBLICATION of findings that ketamine or other *N*-methyl-D-aspartate receptor antagonists accentuate apoptosis in the newborn brain,¹ and that commonly used anesthetic agents (isoflurane, midazolam, and nitrous oxide) not only enhance neuroapoptosis but also promote long-term learning deficits,² sparked controversy in the pages of *ANESTHESIOLOGY*.³ This editorial aims to update anesthesiologists on further investigations on the neurotoxic effects of anesthetic agents and methods for extrapolating neurodevelopmental data from animal models to humans, in order to reexamine the clinical applicability of these findings.

Anesthetic-induced Neurotoxicity: A Brief Update

Neurodegenerative changes after anesthesia occur at both ends of the life span. Epidemiologic observations suggested that onset of Alzheimer disease was related to cumulative anesthetic exposure before the age of 50 yr.⁴

This article is featured in "This Month in Anesthesiology." Please see this issue of *ANESTHESIOLOGY*, page 5A.

Animal studies confirmed that inhaled anesthetics enhance the production, aggregation, and neurotoxicity of amyloid- β peptides,⁵ appearance of brain plaques and learning/memory deficits characterizing Alzheimer disease,⁶ and increased apoptosis,⁶ probably in hippocampal areas.⁷ This report, however, focuses on the anesthetic neurotoxicity after fetal-neonatal exposure, coincident with developmentally occurring apoptosis, which affects 0.5-1% of rodent neurons and more than 50% of human neurons.⁸

The original finding that *N*-methyl-D-aspartate receptor antagonists such as ketamine enhance apoptosis in immature neurons has been confirmed in different animal models and by multiple authors (reviewed recently by Mellon *et al.*⁹). Anesthetic neurotoxicity peaks at postnatal day 7 (P7) in rats^{2,10-12} and requires prolonged exposures in rats and monkeys.^{2,10,12-16} Single large doses of ketamine (50 mg/kg) or benzodiazepines activate apoptosis in mice,^{17,18} signifying developmental differences across species.¹⁹ Further, anesthetic neurotoxicity primarily results from apoptosis in rodents,^{2,10-12,17,18} whereas infant monkeys at P5 (but not at P35) exhibit both excitotoxicity and apoptosis.^{10,13,15,16}

Despite the accumulating data, practicing anesthesiologists must consider important limitations in applying such experimental results to clinical practice. These include developmental differences across mammalian species, the huge doses and prolonged exposures required to produce

Accepted for publication April 19, 2007. Supported by grant No. HD50009 from the National Institute for Child Health and Human Development and grant Nos. RR018765 and RR016460 from the National Center for Research Resources, National Institutes of Health, Bethesda, Maryland.